Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10970757 | 0.87 | GAA (0.48) | CYP11B2CYP11B1PTGS2CYP19A1MAOB | |
| SCHEMBL9220414 | 0.82 | S1PR1 (0.40) | CYP11B2CYP11B1MAOBALDH1A1MEN1 | |
| SCHEMBL9220800 | 0.80 | CYP11B1 (0.50) | CYP11B2CYP11B1PTGS2CYP19A1MAOB | |
| SCHEMBL9215916 | 0.79 | HRH3 (0.38) | CYP11B2CYP11B1PTGS2MAOBALDH1A1 | |
| SCHEMBL2117296 | 0.78 | ERN1 (0.35) | CYP11B2CYP11B1PTGS2CYP19A1LMNA | |
| SCHEMBL1589975 | 0.78 | ALDH1A1 (0.44) | PTGS2MAOBMAOAALDH1A1GAA | |
| SCHEMBL9165973 | 0.77 | MAOA (0.51) | MAOBMAOA | |
| SCHEMBL19600976 | 0.76 | MIF (0.40) | CYP19A1MAOBMAOAMIFCYP26A1 | |
| SCHEMBL29720433 | 0.76 | MIF (0.40) | CYP19A1MAOBMAOAMIFCYP26A1 | |
| SCHEMBL30715511 | 0.76 | CYP11B2 (0.56) | CYP11B2CYP11B1PTGS2CYP19A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| EP-0524517-B1 | Substituted 3,4-dihydronaphthalenes, medicament containing them and process for their preparation | GRUENENTHAL GMBH (DE) | 1995-06-21 | — | — | EP | disclosed |
| US-5254731-A | Enzyme inhibitors; leukotriene disorders | GRUENENTHAL GMBH (DE) | 1993-10-19 | — | — | US | disclosed |
| EP-0524517-A1 | Substituted 3,4-dihydronaphthalenes, medicament containing them and process for their preparation | Grünenthal GmbH (DE) | 1993-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | CYP11B2 1469/4885CYP11B1 1393/4885PTGS2 1179/4885 |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, H1-3, H1-5 | CYP11B2 984/4885CYP11B1 861/4885PTGS2 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.